The purpose of this study is to gather information about post-market performance of DuraGen
      Secure.The aim of this post market clinical follow-up (PMCF) is to obtain post market
      clinical data to evaluate the presence of unintended residual risks associated with the use
      of DuraGen Secure that were not anticipated or identified in the animal studies, bench
      studies or clinical evaluation report.

Duragen® Secure Post Marketing Clinical Follow-up (PMCF)

Dura Mater Nick Cut or Tear

Surgery

Patient outcome from the procedure (recovered without sequelae, ongoing with medical intervention, ongoing with surgical intervention, deceased, other)

Adverse event that occured 72 hours post-operatively

Adverse event that occured between days 4-14 post-operatively

Adverse event that occured between days 15-30 post-operatively

Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted

Duragen® Secure Post Marketing Clinical Follow-up (PMCF)

About this trial

Study ID

Status

Type

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?